Ratings Yield10 Bioscience, Inc.

Equities

YTEN

US98585K8624

Real-time Estimate Cboe BZX Other stock markets 03:39:37 2024-04-29 pm EDT			5-day change	1st Jan Change
0.227 ^USD	+2.34%		-11.92%	-3.93%

Apr. 01	Transcript : Yield10 Bioscience, Inc., Q4 2023 Earnings Call, Apr 01, 2024
Apr. 01	Yield10 Bioscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
YIELD10 BIOSCIENCE, INC.	-3.93%	3.42M	-
IQVIA HOLDINGS INC.	+1.52%	42.75B	B
LONZA GROUP AG	+47.70%	41.61B	A
MODERNA, INC.	+12.10%	41.34B	B-
CELLTRION, INC.	-8.83%	26.59B	C
ICON PUBLIC LIMITED COMPANY	+6.92%	25.49B	B-
ALNYLAM PHARMACEUTICALS, INC.	-23.26%	18.12B	B
MEDPACE HOLDINGS, INC.	+30.13%	12.24B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.50%	11.76B	C+
UNITED THERAPEUTICS CORPORATION	+8.29%	11B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes